Top StoriesDepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
By DepYmed, Inc. | March 19, 2024 DepYmed to Meet with Investors at the BIO CEO and Investor Conference
By DepYmed, Inc. | February 21, 2024 DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
By DepYmed, Inc. | February 7, 2024 DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
By DepYmed, Inc. | October 3, 2023 DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023
By DepYmed, Inc. | September 27, 2023 DepYmed to Meet with Investors at the LSX World Congress USA in Boston on September 13-14, 2023
By DepYmed, Inc. | September 7, 2023 DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | June 14, 2023 DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | May 31, 2023 DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | November 16, 2022 DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
By DepYmed, Inc. | May 23, 2022 DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | May 3, 2022 Role of a New Generation of PTP1B Inhibitors Against a Novel Intracellular Checkpoint in Cancer
By DepYmed, Inc. | March 10, 2022 DepYmed Appoints Peter Van Ess, Pharm.D., Ph.D. as VP of Early Development
By DepYmed, Inc. | August 5, 2021 Depymed, Inc. Announces $8.3 Million Financing
By DepYmed, Inc. | April 7, 2021 |
Shape Divider - Style triangle
Archived News
-
2018
-
2017
-
2016
-
2015
-
2014
<
>
December 24, 2015 (Newsday - Business)
DepYmed snags $100,000 to develop new breast cancer drug
December 23, 2015 (Northwell Health
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $50,000 Grant and $50,000 Investment in DepYmed
December 22, 2015 (InnovateLI)
DepYmed wins Accelerate funding
March 31, 2015 (Accelerate LI)
Accelerate LI Announces 14 Hottest Startups
March 17, 2015 (InnovateLI)
Clinical trials for DepYmed
February 17, 2015 (DepYmed, Inc)
DepYmed, Inc. Announces Appointment of New President and CEO
DepYmed snags $100,000 to develop new breast cancer drug
December 23, 2015 (Northwell Health
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $50,000 Grant and $50,000 Investment in DepYmed
December 22, 2015 (InnovateLI)
DepYmed wins Accelerate funding
March 31, 2015 (Accelerate LI)
Accelerate LI Announces 14 Hottest Startups
March 17, 2015 (InnovateLI)
Clinical trials for DepYmed
February 17, 2015 (DepYmed, Inc)
DepYmed, Inc. Announces Appointment of New President and CEO
Shape Divider - Style triangle
Publications
Shape Divider - Style triangle